Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

Buftoad: A Meme Coin for Psychedelics

Apr 2 • 3 min read

In a world where meme coins often surface with the promise of quick riches but little substance, Buftoad emerges as a beacon of purpose and potential. Launched on the vibrant Solana blockchain, this innovative meme coin quickly turned heads, not just for its financial allure but for its noble mission. At its heart, Buftoad aims…

Preparing for the Horizons: Perspectives on Psychedelics Event in New York

Mar 27 • 4 min read

Horizons: Perspectives on Psychedelics stands as a beacon for those intrigued by the enigmatic world of psychedelic research and culture. As Horizons approaches its 16th year, this seminal event promises to unfold over three enlightening days, from May 9-11, 2024, at the prestigious New York Academy of Medicine. This year’s gathering is not just an…

atai Life Sciences Applauds Breakthrough in Depression Treatment with Beckley Psytech’s DMT Study

Mar 27 • 3 min read

atai Life Sciences, trading under NASDAQ:ATAI and ETR:9VC, recently announced the encouraging findings from a study conducted by its investee, Beckley Psytech, on a pioneering DMT formulation, BPL-003, for individuals struggling with treatment-resistant depression. During this open-label Phase 2a investigation, a select group of patients received a single dose of BPL-003. This novel, synthetic formulation…

Insurance Coverages To Help Bring Psychedelic Treatments to Market

Mar 22 • 4 min read

The revitalization of psychedelic substances for therapeutic applications has ignited significant interest in their potential as breakthrough treatments, driving a flurry of research and efforts to introduce these therapies into the market. In the United States, the journey to market for regulated substances is stringent, requiring extensive research, clinical tests, and trials overseen by the…

Studying the Effects of Natural Psilocybin Versus Synthetic Versions

Mar 21 • 3 min read

Recent studies have shed light on the intriguing potential of hallucinogenic mushrooms, specifically those containing psilocybin, in offering therapeutic benefits for individuals suffering from anxiety, post-traumatic stress disorder (PTSD), and obsessive-compulsive disorders (OCD). Spearheaded by Professor Bernard Lerer, this research delves into the realm of psychedelics as a promising avenue for treating psychiatric conditions that…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354